Literature DB >> 2743650

Type III Machado-Joseph disease in a Japanese family: a clinicopathological study with special reference to the peripheral nervous system.

T Kanda1, E Isozaki, S Kato, H Tanabe, M Oda.   

Abstract

The clinical and pathological findings in a 58-year-old Japanese man suffering from type III Machado-Joseph disease are reported. The patient became affected at the age of 50 years and presented cerebellar ataxia, progressive external ophthalmoplegia and muscular atrophy, although extrapyramidal signs were never detected throughout the whole course of his disease. His mother, sister and son presented progressive ataxia in the third or fourth decade. The mode of inheritance is considered to be autosomal dominant. Pathological examination revealed severe involvement of the dentato-rubral, ponto-cerebellar and subthalamopallidal systems, spinocerebellar tracts and Clarke's column, cranial motor nuclei including the oculomotor systems and anterior horn cells. The involvement of the substantia nigra was relatively mild, and the nerve cells in the inferior olivary nucleus were well preserved. The distal portion of peripheral nerves was severely damaged. Although the striking feature of Machado-Joseph disease is a considerable variability in the individual clinical expression, there have not been many autopsied cases of this disease and efforts to clarify the clinico-pathological correlation in each phenotype have scarcely been made. Relatively mild changes in the substantia nigra and severe involvement of the peripheral nervous system, as in our case, may be the pathological hallmarks of the type III disorder.

Entities:  

Mesh:

Year:  1989        PMID: 2743650

Source DB:  PubMed          Journal:  Clin Neuropathol        ISSN: 0722-5091            Impact factor:   1.368


  8 in total

1.  Changes of unmyelinated nerve fibers in sural nerve in amyotrophic lateral sclerosis, Parkinson's disease and multiple system atrophy.

Authors:  T Kanda; H Tsukagoshi; M Oda; K Miyamoto; H Tanabe
Journal:  Acta Neuropathol       Date:  1996       Impact factor: 17.088

2.  Mosaicism of the CAG repeat in CNS tissue in relation to age at death in spinocerebellar ataxia type 1 and Machado-Joseph disease patients.

Authors:  P Maciel; I Lopes-Cendes; S Kish; J Sequeiros; G A Rouleau
Journal:  Am J Hum Genet       Date:  1997-04       Impact factor: 11.025

3.  Spinocerebellar ataxias types 2 and 3: degeneration of the pre-cerebellar nuclei isolates the three phylogenetically defined regions of the cerebellum.

Authors:  U Rüb; K Gierga; E R Brunt; R A I de Vos; M Bauer; L Schöls; K Bürk; G Auburger; J Bohl; C Schultz; M Vuksic; G J Burbach; H Braak; T Deller
Journal:  J Neural Transm (Vienna)       Date:  2005-03-23       Impact factor: 3.575

4.  Delirium associated with Joseph disease.

Authors:  Y Fukutani; K Katsukawa; R Matsubara; K Kobayashi; I Nakamura; N Yamaguchi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-11       Impact factor: 10.154

5.  Correlation between CAG repeat length and clinical features in Machado-Joseph disease.

Authors:  P Maciel; C Gaspar; A L DeStefano; I Silveira; P Coutinho; J Radvany; D M Dawson; L Sudarsky; J Guimarães; J E Loureiro
Journal:  Am J Hum Genet       Date:  1995-07       Impact factor: 11.025

6.  Brain stem atrophy in Joseph disease: a morphometric study using two-dimensional (area) measurement by computed tomography.

Authors:  Y Fukutani; K Katsukawa; Y Ishizaki; K Kobayashi; I Nakamura
Journal:  J Neurol       Date:  1991-07       Impact factor: 4.849

7.  Regional cerebral blood flow measured with N-isopropyl-p-[123I]iodoamphetamine single-photon emission tomography in patients with Joseph disease.

Authors:  N Takahashi; I Odano; M Nishihara; T Yuasa; K Sakai
Journal:  Eur J Nucl Med       Date:  1994-07

8.  Motor neuronopathy with dropped hands and downbeat nystagmus: a distinctive disorder? A case report.

Authors:  Nimish J Thakore; Erik P Pioro; Janet C Rucker; R John Leigh
Journal:  BMC Neurol       Date:  2006-01-12       Impact factor: 2.474

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.